Tech Company Financing Transactions
Inscripta Funding Round
Inscripta, based in Boulder, secured $125 million from Paladin Capital Group, JS Capital Management and Oak HC/FT.
Transaction Overview
Company Name
Announced On
12/11/2019
Transaction Type
Venture Equity
Amount
$125,000,000
Round
Series D
Investors
Proceeds Purpose
The new funds will be used to accelerate applications expansion and commercialization of the company's revolutionary Onyx Digital Genome Engineering platform.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
5500 Central Ave.
Boulder, CO 80301
USA
Boulder, CO 80301
USA
Phone
Website
Email Address
Not Recorded
Overview
Inscripta is a gene editing technology company dedicated to creating the tools needed to revolutionize how we feed, fuel, and heal humanity.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sri Kosaraju
Chief Financial Officer
Ronald McGrath
Chief Technical Officer
Michael Graige
VP - General Counsel
Dianna Devore
VP - Operations
Thomas Rosso
Browse more venture capital transactions:
Prev: 12/11/2019: Quellis Biosciences venture capital transaction
Next: 12/11/2019: Taqtile venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to document every notable VC transaction. All VC database entries reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs